Effect of rabetalol combined with low-dose aspirin on serum levels of miR-181b and miR-210 in pregnant women with hypertension disorders

Objective To explore the effect of rabetalol combined with low-dose aspirin in the treatment of hypertension disorders and influences on the expression of microRNA-181b(miR-181b)and microRNA-210(miR-210). Methods A total of 150 patients with hypertension during pregnancy were randomly divided into study group and control group, with 75 cases in each group. The control group was treated with labelol, and the patients in the study group were treated with low-dose aspirin enteric-coated tablets. The clinical efficacy, coagulation function, adverse pregnancy outcomes, serum miR-181b and miR-210 expression levels were compared between the two groups. Results After treatment, the clinical efficacy of the study group was significantly higher than that in the control group(P<0.05); prothrombin time(PT), activated partial thromboplastin time(APTT)and plasma thrombin time(TT)were all significantly longer than those in the control group, the levels of plasma fibrinogen(Fib)and D-dimer were significantly lower than the control group(P<0.05); the incidence of adverse pregnancy outcomes in the study group was significantly lower than that in the control group(P<0.05); the expression levels of serum miR-18b and miR-210 in the study group were significantly lower than those in the control group(P<0.05). Conclusion Labelol combined with low-dose aspirin has a good clinical effect for patients with gestational hypertension, which can effectively improve the coagulation function, decrease the incidence of adverse pregnancy outcomes, and reduce the expression levels of serum miR-181b and miR-210.